Manuprasad A

Publications

• Research Article   
  Toxicity profile of weekly regimen of paclitaxel in patients with non-metastatic breast cancer-a real world experience (India)
  Author(s): Praveen Kumar Shenoy, Isharath Ebrahim, Anitha Mary Skaria and Manuprasad A*
  
  Introduction: Taxanes especially paclitaxel is a key chemotherapeutic agent in the management of non-metastatic breast cancer. Different schedules are utilized in management with weekly paclitaxel being one of the common regimes. The weekly regimen has a distinctive toxicity profile. Methods: This retrospective study was done to study the adverse effect profile of weekly paclitaxel used in the treatment of non-metastatic breast cancer. Data were collected from case records of patients who received or were started on weekly paclitaxel single agent or in combination with trastuzumab between May and July 2019. Results: Eighty-eight patient case records were analyzed. The median age was 46.5 yrs (Range 30-67 yrs). The majority of patients received paclitaxel as an adjuvant (N=80, 91%). Sixty-one patients (69%) received.. Read More»
  

  Abstract HTML PDF